Linked Life Data

CASODEX (Tablet)

Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/53

Statements in which the resource exists.
SubjectPredicateObjectContext
dailymed-drugs:53rdf:typehttp://www4.wiwiss.fu-berli...lld:dailymed
dailymed-drugs:53rdf:typedailymed-instance:drugslld:dailymed
dailymed-drugs:53rdfs:labelCASODEX (Tablet)lld:dailymed
dailymed-drugs:53dailymed-instance:dosageThe recommended dose for CASODEX therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that CASODEX be taken at the same time each day. Treatment with CASODEX should be started at the same time as treatment with an LHRH analogue.<br/>Dosage Adjustment in Renal Impairment:: No dosage adjustment is necessary for patients with renal impairment . Dosage Adjustment in Hepatic Impairment: No dosage adjustment is necessary for patients with mild to moderate hepatic impairment. Although there is a 76% (5.9 and 10.4 days for normal and impaired patients, respectively) increase in the half-life of the active enantiomer of bicalutamide in patients with severe liver impairment (n=4), no dosage adjustment is necessary .lld:dailymed
dailymed-drugs:53dailymed-instance:descripti...CASODEX' (bicalutamide) Tablets for oral administration contain 50 mg of bicalutamide, a non-steroidal antiandrogen with no other known endocrine activity. The chemical name is propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-). The structural and empirical formulas are: Bicalutamide has a molecular weight of 430.37. The pKa' is approximately 12. Bicalutamide is a fine white to off-white powder which is practically insoluble in water at 37��C (5 mg per 1000 mL), slightly soluble in chloroform and absolute ethanol, sparingly soluble in methanol, and soluble in acetone and tetrahydrofuran. CASODEX is a racemate with its antiandrogenic activity being almost exclusively exhibited by the R-enantiomer of bicalutamide; the S-enantiomer is essentially inactive. The inactive ingredients of CASODEX Tablets are lactose, magnesium stearate, hypromellose, polyethylene glycol, polyvidone, sodium starch glycollate, and titanium dioxide.lld:dailymed
dailymed-drugs:53dailymed-instance:clinicalP...Mechanism of Action: CASODEX is a non-steroidal antiandrogen. It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen. When CASODEX is combined with luteinizing hormone-releasing hormone (LHRH) analogue therapy, the suppression of serum testosterone induced by the LHRH analogue is not affected. However, in clinical trials with CASODEX as a single agent for prostate cancer, rises in serum testosterone and estradiol have been noted. In a subset of patients who have been treated with CASODEX and an LHRH agonist, and who discontinue CASODEX therapy due to progressive advanced prostate cancer, a reduction in Prostate Specific Antigen (PSA) and/or clinical improvement (antiandrogen withdrawal phenomenon) may be observed.<br/>Pharmacokinetics:<br/>Absorption:: Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown. Co-administration of bicalutamide with food has no clinically significant effect on rate or extent of absorption.<br/>Distribution:: Bicalutamide is highly protein-bound (96%). See Drug-Drug Interactions below.<br/>Metabolism/Elimination:: Bicalutamide undergoes stereospecific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation. Both the parent and metabolite glucuronides are eliminated in the urine and feces. The S-enantiomer is rapidly cleared relative to the R-enantiomer, with the R-enantiomer accounting for about 99% of total steady-state plasma levels.<br/>Special Populations::<br/>Clinical Studies:<br/>CASODEX 50 mg Daily in Combination with an LHRH-A: In a multicenter, double-blind, controlled clinical trial, 813 patients with previously untreated advanced prostate cancer were randomized to receive CASODEX 50 mg once daily (404 patients) or flutamide 250 mg (409 patients) three times a day, each in combination with LHRH analogues (either goserelin acetate implant or leuprolide acetate depot). In an analysis conducted after a median follow-up of 160 weeks was reached, 213 (52.7%) patients treated with CASODEX-LHRH analogue therapy and 235 (57.5%) patients treated with flutamide-LHRH analogue therapy had died. There was no significant difference in survival between treatment groups (see Figure 1). The hazard ratio for time to death (survival) was 0.87 (95% confidence interval 0.72 to 1.05). Figure 1 - The Kaplan-Meier probability of death for both antiandrogen treatment groups. There was no significant difference in time to objective tumor progression between treatment groups (see Figure 2). Objective tumor progression was defined as the appearance of any bone metastases or the worsening of any existing bone metastases on bone scan attributable to metastatic disease, or an increase by 25% or more of any existing measurable extraskeletal metastases. The hazard ratio for time to progression of CASODEXplus LHRH analogue to that of flutamide plus LHRH analogue was 0.93 (95% confidence interval, 0.79 to 1.10). Figure 2 - Kaplan-Meier curve for time to progression for both antiandrogen treatment groups Quality of life was assessed with self-administered patient questionnaires on pain, social functioning, emotional well-being, vitality, activity limitation, bed disability, overall health, physical capacity, general symptoms, and treatment related symptoms. Assessment of the Quality of Life questionnaires did not indicate consistent significant differences between the two treatment groups.<br/>Safety Data from Clinical Studies using CASODEX 150 mg: CASODEX 150 mg is not approved for use either alone or with other treatments. Two identical multicenter, randomized, open label trials comparing CASODEX 150 mg daily monotherapy to castration were conducted in patients that had locally advanced (T3-4, NX, MO) or metastatic (M1) prostate cancer.lld:dailymed
dailymed-drugs:53dailymed-instance:activeIng...dailymed-ingredient:Bicalut...lld:dailymed
dailymed-drugs:53dailymed-instance:contraind...CASODEX is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet's components. CASODEX has no indication for women, and should not be used in this population, particularly for non-serious or non-life threatening conditions. Further, CASODEX should not be used by women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. CASODEX may cause fetal harm when administered to pregnant women. The male offspring of rats receiving doses of 10 mg/kg/day (plasma drug concentrations in rats equal to approximately 2/3 human therapeutic concentrations*) and above were observed to have reduced anogenital distance and hypospadias in reproductive toxicology studies. These pharmacological effects have been observed with other antiandrogens. No other teratogenic effects were observed in rabbits receiving doses up to 200 mg/kg/day (approximately 1/3 human therapeutic concentrations*) or rats receiving doses up to 250 mg/kg/day (approximately 2 times human therapeutic concentrations*). *Based on a maximum dose of 50 mg/day of bicalutamide for an average 70 kg patient.lld:dailymed
dailymed-drugs:53dailymed-instance:supply50 mg Tablets: (NDC 0310-0705) White, film-coated tablets (identified on one side with "CDX50" and on the reverse with the "CASODEX logo") are supplied in unit dose blisters of 30 tablets per carton (0310-0705-39), bottles of 30 tablets (0310-0705-30) and bottles of 100 tablets (0310-0705-10). Store at controlled room temperature, 20��-25��C (68��-77��F). AstraZeneca Manufactured for AstraZeneca Pharmaceuticals LP Wilmington, DE 19850 By: IPR Pharmaceuticals Inc. Carolina, PR 00984 Made in USA Rev 03���06238848lld:dailymed
dailymed-drugs:53dailymed-instance:genericDr...http://www4.wiwiss.fu-berli...lld:dailymed
dailymed-drugs:53dailymed-instance:activeMoi...dailymed-ingredient:Bicalut...lld:dailymed
dailymed-drugs:53dailymed-instance:inactiveI...dailymed-ingredient:lactoselld:dailymed
dailymed-drugs:53dailymed-instance:inactiveI...dailymed-ingredient:magnesi...lld:dailymed
dailymed-drugs:53dailymed-instance:inactiveI...dailymed-ingredient:hyprome...lld:dailymed
dailymed-drugs:53dailymed-instance:inactiveI...dailymed-ingredient:sodium_...lld:dailymed
dailymed-drugs:53dailymed-instance:inactiveI...dailymed-ingredient:titaniu...lld:dailymed
dailymed-drugs:53dailymed-instance:inactiveI...dailymed-ingredient:polyeth...lld:dailymed
dailymed-drugs:53dailymed-instance:inactiveI...dailymed-ingredient:polyvid...lld:dailymed
dailymed-drugs:53dailymed-instance:possibleD...diseasome-diseases:84lld:dailymed
dailymed-drugs:53dailymed-instance:possibleD...diseasome-diseases:173lld:dailymed
dailymed-drugs:53dailymed-instance:possibleD...diseasome-diseases:634lld:dailymed
dailymed-drugs:53dailymed-instance:possibleD...diseasome-diseases:910lld:dailymed
dailymed-drugs:53dailymed-instance:possibleD...diseasome-diseases:960lld:dailymed
dailymed-drugs:53dailymed-instance:possibleD...diseasome-diseases:1080lld:dailymed
dailymed-drugs:53dailymed-instance:possibleD...diseasome-diseases:1439lld:dailymed
dailymed-drugs:53dailymed-instance:possibleD...diseasome-diseases:1676lld:dailymed
dailymed-drugs:53dailymed-instance:possibleD...diseasome-diseases:2839lld:dailymed
dailymed-drugs:53dailymed-instance:possibleD...diseasome-diseases:3559lld:dailymed
dailymed-drugs:53dailymed-instance:possibleD...diseasome-diseases:3658lld:dailymed
dailymed-drugs:53dailymed-instance:possibleD...diseasome-diseases:3664lld:dailymed
dailymed-drugs:53dailymed-instance:possibleD...diseasome-diseases:3934lld:dailymed
dailymed-drugs:53dailymed-instance:overdosag...Long-term clinical trials have been conducted with dosages up to 200 mg of CASODEX daily and these dosages have been well tolerated. A single dose of CASODEX that results in symptoms of an overdose considered to be life-threatening has not been established. There is no specific antidote; treatment of an overdose should be symptomatic. In the management of an overdose with CASODEX, vomiting may be induced if the patient is alert. It should be remembered that, in this patient population, multiple drugs may have been taken. Dialysis is not likely to be helpful since CASODEX is highly protein bound and is extensively metabolized. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.lld:dailymed
dailymed-drugs:53dailymed-instance:genericMe...Bicalutamidelld:dailymed
dailymed-drugs:53dailymed-instance:fullNameCASODEX (Tablet)lld:dailymed
dailymed-drugs:53dailymed-instance:adverseRe...In patients with advanced prostate cancer treated with CASODEX in combination with an LHRH analogue, the most frequent adverse experience was hot flashes (53%). In the multicenter, double-blind, controlled clinical trial comparing CASODEX 50 mg once daily with flutamide 250 mg three times a day, each in combination with an LHRH analogue, the following adverse experiences with an incidence of 5% or greater, regardless of causality, have been reported. Other adverse experiences (greater than or equal to 2%, but less than 5%) reported in the CASODEX-LHRH analogue treatment group are listed below by body system and are in order of decreasing frequency within each body system regardless of causality. Body as a Whole: Neoplasm; Neck pain; Fever; Chills; Sepsis; Hernia; Cyst Cardiovascular: Angina pectoris; Congestive heart failure; Myocardial infarct; Heart arrest; Coronary artery disorder; Syncope Digestive: Melena; Rectal hemorrhage; Dry mouth; Dysphagia; Gastrointestinal disorder; Periodontal abscess; Gastrointestinal carcinoma Metabolic and Nutritional: Edema; Bun increased; Creatinine increased; Dehydration; Gout; Hypercholesteremia Musculoskeletal: Myalgia; Leg cramps Nervous: Hypertonia; Confusion; Somnolence; Libido decreased; Neuropathy; Nervousness Respiratory: Lung disorder; Asthma; Epistaxis; Sinusitis Skin and Appendages: Dry skin; Alopecia; Pruritus; Herpes zoster; Skin carcinoma; Skin disorder Special Senses: Cataract specified Urogenital: Dysuria; Urinary urgency; Hydronephrosis; Urinary tract disorder<br/>Abnormal Laboratory Test Values:: Laboratory abnormalities including elevated AST, ALT, bilirubin, BUN, and creatinine and decreased hemoglobin and white cell count have been reported in both CASODEX-LHRH analogue treated and flutamide-LHRH analogue treated patients.<br/>Postmarketing Experience:: Uncommon cases of hypersensitivity reactions, including angioneurotic edema and urticaria, and uncommon cases of interstitial lung disease, including interstitial pneumonitis and pulmonary fibrosis, have been reported with CASODEX.lld:dailymed
dailymed-drugs:53dailymed-instance:warningHepatitis:: Rare cases of death or hospitalization due to severe liver injury have been reported post-marketing in association with the use of CASODEX. Hepatotoxicity in these reports generally occurred within the first three to four months of treatment. Hepatitis or marked increases in liver enzymes leading to drug discontinuation occurred in approximately 1% of CASODEX patients in controlled clinical trials. Serum transaminase levels should be measured prior to starting treatment with CASODEX, at regular intervals for the first four months of treatment, and periodically thereafter. If clinical symptoms or signs suggestive of liver dysfunction occur (e.g., nausea, vomiting, abdominal pain, fatigue, anorexia,���flu-like���symptoms, dark urine, jaundice, or right upper quadrant tenderness), the serum transaminases, in particular the serum ALT, should be measured immediately. If at any time a patient has jaundice, or their ALT rises above two times the upper limit of normal, CASODEX should be immediately discontinued with close follow-up of liver function.lld:dailymed
dailymed-drugs:53dailymed-instance:indicatio...CASODEX 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of Stage Dmetastatic carcinoma of the prostate. CASODEX 150 mg daily is not approved for use alone or with other treatments. See CLINICAL PHARMACOLOGY-Clinical Studies- Safety Data from Clinical Studies using CASODEX 150 mg section for additional important safety information regarding CASODEX 150 mg.lld:dailymed
dailymed-drugs:53dailymed-instance:represent...http://www4.wiwiss.fu-berli...lld:dailymed
dailymed-drugs:53dailymed-instance:routeOfAd...http://www4.wiwiss.fu-berli...lld:dailymed
dailymed-drugs:53dailymed-instance:nameCASODEXlld:dailymed
http://www4.wiwiss.fu-berli...dailymed-instance:producesD...dailymed-drugs:53lld:dailymed
diseasome-diseases:84diseasome-instance:possible...dailymed-drugs:53lld:diseasome
diseasome-diseases:173diseasome-instance:possible...dailymed-drugs:53lld:diseasome
diseasome-diseases:634diseasome-instance:possible...dailymed-drugs:53lld:diseasome
diseasome-diseases:910diseasome-instance:possible...dailymed-drugs:53lld:diseasome
diseasome-diseases:960diseasome-instance:possible...dailymed-drugs:53lld:diseasome
diseasome-diseases:1080diseasome-instance:possible...dailymed-drugs:53lld:diseasome
diseasome-diseases:1439diseasome-instance:possible...dailymed-drugs:53lld:diseasome
diseasome-diseases:1676diseasome-instance:possible...dailymed-drugs:53lld:diseasome
diseasome-diseases:2839diseasome-instance:possible...dailymed-drugs:53lld:diseasome
diseasome-diseases:3559diseasome-instance:possible...dailymed-drugs:53lld:diseasome
diseasome-diseases:3658diseasome-instance:possible...dailymed-drugs:53lld:diseasome
diseasome-diseases:3664diseasome-instance:possible...dailymed-drugs:53lld:diseasome
diseasome-diseases:3934diseasome-instance:possible...dailymed-drugs:53lld:diseasome